The Complete Guide to Grant Writing in Pharma & Drug Development
From naming every major grant that exists, to navigating regulatory approval, preparing for Series A/B/C fundraising, and running airtight due diligence — this is the definitive resource for biotech and pharmaceutical companies seeking funding.
Bringing a drug to market costs an average of $2.6 billion and takes 10–15 years. No single company funds that journey alone. The most successful pharma and biotech companies layer non-dilutive grant funding on top of equity raises, using government and philanthropic grants to extend runway, validate science, and enter each funding round from a position of strength.
This guide covers everything: every major named grant, how to write a winning application, what due diligence really looks like, how to position for Series A through C, and where to get expert support.
Part 1: The Complete Pharma Grant Directory
Below is a comprehensive, named reference of every major grant and funding mechanism available to pharmaceutical and drug development companies — from early discovery through late-stage clinical development.
Federal US Grants & Programs
Small Business Innovation Research Grant
SBIR — R43 (Phase I) / R44 (Phase II)
America’s largest early-stage seed funding program for small businesses conducting R&D with commercial potential. Phase I awards fund feasibility (~$300K); Phase II funds full R&D (~$2M). Offered by NIH, FDA, CDC, NSF, DoD, and other federal agencies. Non-dilutive.
Typical award: Phase I ~$300K | Phase II ~$2M · Type: Non-dilutive · Agency: NIH / Multi-agency
Small Business Technology Transfer Grant
STTR — R41 (Phase I) / R42 (Phase II)
Like SBIR, but requires a formal partnership between the small business and a non-profit research institution (university or federal lab). Designed to bridge academic discovery and commercial application. At least 30% of the work must be performed by the research institution.
Requirement: Academic/non-profit partner · Type: Non-dilutive · Agency: NIH / Multi-agency
BARDA Broad Agency Announcement
BARDA BAA
The Biomedical Advanced Research and Development Authority funds late-stage development of medical countermeasures — vaccines, drugs, diagnostics — for chemical, biological, radiological, nuclear, pandemic, and emerging infectious disease threats. Awards can reach hundreds of millions. Continuous rolling submission.
Stage: Late-stage development · Agency: BARDA / HHS · Type: Non-dilutive
NIH Research Project Grant
R01
NIH’s primary mechanism for independent, investigator-initiated research. Awarded for 3–5 years. Core to academic-industry collaboration models and preclinical validation work. Highly competitive (~20% success rate) but confers major credibility.
Duration: 3–5 years · Direct costs: Up to $500K/year · Agency: NIH
Exploratory / Developmental Research Grant
R21
A two-year exploratory NIH grant for novel, high-risk/high-reward ideas that lack sufficient preliminary data for an R01. Ideal for early-stage drug target validation or new platform technologies. Lower budget but a faster path to funding for innovative concepts.
Duration: 2 years · Up to: $275K total · Agency: NIH
NIH Cooperative Agreement
U01 / U54
Cooperative research grants where NIH program staff are substantially involved in the research design and execution. U54 funds large multi-site research centers. Common in NCATS (National Center for Advancing Translational Sciences) translational programs.
Type: Cooperative · Agency: NIH / NCATS
NIH Fast-Track SBIR/STTR
Fast-Track (NIH only)
Allows eligible applicants to combine Phase I and Phase II SBIR/STTR applications into a single submission, eliminating the funding gap between phases. Reviewed once; funded in two tranches based on milestone completion. Ideal for companies with strong preliminary data ready for both phases.
Benefit: No gap between Phase I and II · Agency: NIH
Commercialization Readiness Pilot Program
CRP Program
NIH program providing technical assistance and late-stage development support to SBIR/STTR awardees who have completed Phase II but need additional support to reach commercial viability. Bridges the gap between grant-funded R&D and private capital investment.
Stage: Post-Phase II · Agency: NIH SEED
Small Business Transition Grant for New Entrepreneurs
PAR-24-131 / 132 / 133 / 134
NIH grants specifically designed for researchers transitioning from academic or industry positions into small business R&D. Covers clinical trial required and not-required tracks across both SBIR (R43/R44) and STTR (R41/R42) mechanisms.
Target: New entrepreneurs · Agency: NIH
Technical and Business Assistance Supplement
TABA
An administrative supplement available to SBIR/STTR awardees for accessing third-party technical and business services — market research, IP strategy, regulatory consulting, and commercialization planning — at no additional cost to the company. Applicants can also request a free TABA Needs Assessment Report.
Type: Administrative supplement · Cost to company: $0
Blueprint Neurotherapeutics Network
BPN Program
NIH Blueprint and NIAAA-sponsored program providing milestone-driven drug discovery support for small molecules and biologics targeting disorders of the nervous system. Includes expert scientific guidance alongside funding — essentially a pharma-like partnership model within the NIH ecosystem.
Focus: CNS therapeutics · Agency: NIH Blueprint / NIAAA
NSF SBIR — Pharmaceutical Technologies
NSF SBIR / STTR
The National Science Foundation’s SBIR/STTR program specifically funds pharmaceutical technology innovations — novel drugs, drug delivery platforms, formulation technologies, and manufacturing process innovations. Note: NSF paused new Project Pitch submissions in late 2025 pending reauthorization. The next standard receipt date is September 5, 2026.
Agency: NSF · Apply at: seedfund.nsf.gov
Department of Defense (DoD) Programs
DARPA Biological Technologies Office
DARPA BTO
Funds high-risk, high-reward biological and pharmaceutical research with defense relevance. Past programs include the Pandemic Prevention Platform (P3), which accelerated antibody discovery for infectious disease countermeasures including work that informed COVID-19 therapeutic development. DARPA tolerates failure in ways NIH cannot.
Risk profile: High / Transformative · Agency: DARPA / DoD
Congressionally Directed Medical Research Programs
CDMRP
Disease-specific DoD research grants directed by Congress. Programs include the Breast Cancer Research Program (BCRP), Prostate Cancer Research Program (PRCRP), Lung Cancer Research Program (LCRP), ALS Research Program, Gulf War Illness Research Program, Tick-Borne Disease Research Program, and Rare Pediatric Disease Research Program. Often includes translational research awards with industry-eligible tracks.
Agency: DoD / USAMRAA · Areas: Oncology, ALS, rare disease, infectious disease
Defense Threat Reduction Agency Grants
DTRA Basic Research
Supports basic and applied research in chemical and biological defense, including development of medical countermeasures against CBRN (chemical, biological, radiological, nuclear) threats. Often partners with BARDA for downstream development pipeline funding.
Focus: CBRN defense · Agency: DTRA / DoD
Private & Philanthropic Funders
Wellcome Trust — Seeding Drug Discovery
Wellcome SDD
Wellcome’s flagship drug discovery grant funding early-stage medicinal chemistry and target validation. Supports projects across infectious disease, neglected tropical diseases, CNS disorders, and metabolic diseases through to clinical candidate nomination. One of the most prestigious grants in early-stage pharma.
Funder: Wellcome Trust (UK) · Stage: Discovery through candidate nomination
Bill & Melinda Gates Foundation — Grand Challenges
Gates Grand Challenges
Funds innovative solutions to global health problems, including drug discovery for neglected and infectious diseases. Active co-funder of the Gr-ADI (Gram-Negative Antibiotic Discovery Innovator) Grand Challenge alongside Wellcome and the Novo Nordisk Foundation — one of the largest recent AMR funding initiatives.
Funder: BMGF · Focus: Global health, neglected disease, AMR
CARB-X Accelerator Awards
CARB-X
The world’s largest public-private partnership dedicated to early antibacterial drug development. Funded by BARDA, Wellcome, the Gates Foundation, the Novo Nordisk Foundation, and multiple governments. Has funded over 100 projects in 12 countries. Open calls in four areas: therapeutics for gram-negative bacteria, prevention of invasive disease, diagnostics for neonatal sepsis, and proof-of-concept for lower-respiratory-tract infection diagnostics.
Track record: 100+ projects funded globally · Focus: Antimicrobial resistance
Novo Nordisk Foundation Research Grants
NNF Research Grants
Provides significant funding for biomedical and pharmaceutical research, particularly in metabolic disease, cardiovascular disease, and antimicrobial resistance. Co-funder of CARB-X and the Gr-ADI Grand Challenge. One of the largest private foundations in life sciences globally.
Funder: Novo Nordisk Foundation · HQ: Denmark
American Cancer Society Research Grants
ACS Research Grants
Funds basic, clinical, and translational cancer research. Categories include Research Scholar Grants, Institutional Research Grants, and Mission Boost Grants for high-impact near-term translational projects in oncology drug development. Industry-affiliated investigators are eligible for some mechanisms.
Funder: American Cancer Society · Focus: Oncology
National MS Society — Fast Forward Program
NMSS Fast Forward
Industry-partnered grant program providing milestone-driven funding directly to biotech companies developing therapies for multiple sclerosis. Unique in that no academic PI is required — companies apply directly. Milestone payments tied to clinical and regulatory achievements.
Funder: National Multiple Sclerosis Society · Focus: MS therapeutics
International & European Programs
European Innovation Council Accelerator
EIC Accelerator
The EU’s flagship program for deep tech and life science SMEs. Provides up to €2.5M in non-dilutive grant funding plus up to €15M in equity investment. Formerly the Horizon 2020 SME Instrument, now part of Horizon Europe. One of the most competitive and prestigious awards for European biotech startups.
Grant: Up to €2.5M · Equity: Up to €15M · Funder: European Commission
Innovative Health Initiative
IHI (formerly IMI / IMI2)
The EU-industry public-private partnership under Horizon Europe, with a €2.4B total budget. Funds collaborative research bringing together pharma companies, biotech SMEs, academic institutions, patient organizations, and regulators. Focuses on prevention, diagnosis, and treatment across all disease areas.
Total budget: €2.4B · Funder: EU + Industry in-kind
European Research Council Grants
ERC Starting / Consolidator / Advanced
The EU’s most prestigious individual researcher grants. Starting Grants (up to €1.5M) for early-career researchers; Consolidator Grants (up to €2M); Advanced Grants (up to €2.5M) for established scientists. Strong track record in translational pharmaceutical research, particularly relevant for academic founders.
Up to: €2.5M · Funder: EU / Horizon Europe
Innovate UK Smart Grants
Innovate UK
UK Research and Innovation’s grant program for disruptive R&D-based innovation by SMEs and large businesses. Life sciences and medtech rounds open regularly as part of the UK’s broader biomedical investment strategy. Accessible to companies incorporated in the UK.
Funder: UKRI / Innovate UK · Eligibility: UK-incorporated entities
Drugs for Neglected Diseases Initiative
DNDi
A non-profit research organization that partners with academic institutions and pharma companies to develop drugs for neglected tropical diseases. Provides milestone-driven funding and full drug development support through clinical proof of concept. Strong track record in Chagas disease, visceral leishmaniasis, and sleeping sickness.
Funder: DNDi / Multi-donor · Focus: Neglected tropical diseases
Part 2: How to Write a Winning Pharma Grant Application
Grant writing in drug development demands a different skill set than academic or nonprofit writing. Reviewers are looking for scientific rigor, commercial viability, and regulatory awareness — simultaneously. Here is the six-step framework used by successful applicants.
Identify the Right Grant Before You Write
Misalignment between your program and the grant mechanism is the leading cause of avoidable rejection. Spend time mapping your molecule’s stage, disease area, company size, and commercial intent to the appropriate funder before investing in writing.
- Match your Technology Readiness Level (TRL) to the grant phase — don’t submit Phase II ideas to Phase I mechanisms
- Review funded abstracts on NIH Reporter, SBIR.gov, and BARDA’s award database to understand what gets funded
- Contact the Program Officer before submitting — a 20-minute call can save months of misdirected effort
- Check whether the agency has a specific topic area matching your therapeutic focus
Build a Fundable Scientific Narrative
The best pharma grant applications tell a story: unmet medical need → mechanistic hypothesis → your solution → why your team, why now. Each section must logically compel the reader toward the next.
- Open with burden of disease data — quantify the unmet need in epidemiological and economic terms
- Establish your mechanism of action with clear preclinical rationale and target validation evidence
- Articulate your competitive differentiation: what does your molecule do that nothing else can?
- Frame milestones as risk-reduction events, not just tasks — show how each aim de-risks the program
Master the Specific Aims Page (NIH Applications)
For NIH applications, the Specific Aims page is the single most important page you will write. Reviewers form strong impressions from this one-page overview that are rarely reversed by the rest of the application. Structure it as follows:
- Paragraph 1: The hook — unmet need and the gap in current approaches
- Paragraph 2: Your solution, central hypothesis, and why you’re positioned to solve it
- Aims section: 2–3 aims, each with a falsifiable hypothesis and measurable expected outcomes
- Final paragraph: Impact statement — what changes in this disease space if you succeed?
Demonstrate Commercial Viability (SBIR & BARDA)
Unlike academic grants, SBIR and BARDA applications require you to articulate a clear path to commercialization. Reviewers evaluate your commercial feasibility alongside your science.
- Include a Total Addressable Market (TAM) analysis with credible, cited data sources
- Outline your IP strategy: patents filed or pending, freedom to operate assessment completed
- Map your regulatory pathway: IND-enabling studies → Phase I → FDA/EMA approval strategy
- Include letters of support from key opinion leaders, potential partners, or early customers
- Show a realistic 5-year financial model that accounts for grant funding and private capital needs
Assemble a Credible Team Section
Grant agencies fund teams as much as ideas. Reviewers look for domain expertise, relevant track records, and the advisory infrastructure to manage program execution.
- Ensure coverage of: drug discovery/chemistry, ADMET/pharmacology, regulatory affairs, and business development
- Scientific Advisory Board members with strong publication and advisory records signal credibility
- Highlight relevant prior grant history and successful exits from team members
- Use subcontracts with recognized CROs or academic collaborators to fill expertise gaps transparently
Budget Justification and Milestone-Driven Planning
A poorly constructed budget undermines credibility, even for strong science. Every line item should be justifiable on demand. Milestones must be specific, measurable, and achievable within the award period.
- Obtain quotes for major line items — CRO studies, CMC work, assay development
- Justify personnel effort with realistic FTE allocations; over-allocating PI time is a common red flag
- Construct a Gantt chart with dependencies to show you understand the critical path
- Define explicit Go/No-Go criteria for each milestone — this demonstrates scientific rigor and risk awareness
Part 3: Regulatory Approval — What Funders Need to See
Understanding the regulatory pathway isn’t optional — it’s central to every grant application and investor pitch. Funders need to see that you know what it takes to bring your drug through to approval.
The US FDA Pathway
- Target Identification & Lead Optimization — Identify a validated biological target, screen compound libraries, and optimize lead series for potency, selectivity, and preliminary ADMET properties. Pre-grant activity, typically self-funded or angel-backed.
- IND-Enabling Studies — Required before first-in-human trials. Includes GLP toxicology studies, pharmacokinetics, safety pharmacology, and CMC development. Often funded by SBIR Phase II or BARDA. Typically 18–36 months.
- Investigational New Drug (IND) Application — Submitted to FDA requesting authorization to administer the drug to humans. FDA has 30 days to respond. Must include a clinical protocol, investigator information, and full preclinical data package.
- Phase I Clinical Trials — First-in-human studies in 20–80 subjects. Establish safety, tolerability, PK/PD parameters, and maximum tolerated dose. Typically 1–2 years.
- Phase II Clinical Trials — Proof-of-concept in 100–300 patients. Establish preliminary efficacy, dose-ranging, and further safety data. Failure rate approximately 60%. The critical inflection point for Series B/C fundraising.
- Phase III Pivotal Trials — Randomized controlled trials in 1,000–3,000+ patients. Demonstrate efficacy and safety for NDA/BLA submission. Typically 3–5 years and $100M–$500M. Usually partner-funded or post-IPO.
- NDA / BLA Submission & FDA Review — Standard review is 10–12 months; Priority Review is 6 months. The PDUFA date sets the review clock.
Key FDA Designation Programs
Securing an FDA designation can dramatically accelerate your development timeline, strengthen your grant application, and increase investor confidence. Here are the main designations pharma companies should pursue:
| Designation | Key Criteria | Primary Benefit |
|---|---|---|
| Fast Track | Serious condition + unmet medical need | Rolling review; more frequent FDA interaction |
| Breakthrough Therapy | Substantial improvement over available therapy (clinical evidence required) | Priority Review + intensive FDA guidance and senior involvement |
| Accelerated Approval | Surrogate endpoint reasonably likely to predict clinical benefit | Approval on surrogate; confirmatory trials required post-approval |
| Priority Review | Significant improvement in safety or effectiveness | 6-month review vs. standard 10–12 months |
| Orphan Drug | Disease affecting fewer than 200,000 US patients | 7-year market exclusivity + 50% tax credit on clinical trial costs |
| QIDP | Qualifying infectious disease product | 5-year market exclusivity extension + Fast Track and Priority Review |
| Rare Pediatric Disease | Rare disease primarily affecting children | Priority Review Voucher upon approval (tradeable; worth $100M+) |
Part 4: Due Diligence in Drug Development
Whether you’re preparing for a major grant review, a licensing deal, or an equity investment round, the due diligence process in pharma follows a consistent and comprehensive framework. Preparation is the foundation of credibility.
Scientific & Technical Due Diligence
- Validated drug target with published biological rationale
- Reproducible preclinical efficacy data, both in vitro and in vivo
- Established structure-activity relationship (SAR) data with clear optimization logic
- Full ADMET profile: absorption, distribution, metabolism, excretion, and toxicity
- Biomarker strategy for patient selection and pharmacodynamic endpoints
- Mechanism of action elucidated at the molecular level
- Manufacturing feasibility and synthetic route scalability assessed
Regulatory & Clinical Due Diligence
- Pre-IND meeting minutes with FDA (highly valued by both grant reviewers and investors)
- Written regulatory strategy document covering key agency interactions and milestones
- IND-enabling study plan with CRO agreements in place or in negotiation
- Clinical trial design aligned with FDA endpoint guidance for your indication
- CMC (Chemistry, Manufacturing, Controls) development plan documented
- GLP toxicology study reports available (or timelines confirmed)
- FDA designations obtained or planned — Fast Track, Orphan, Breakthrough, etc.
Intellectual Property Due Diligence
- Independent patent landscape analysis conducted by qualified IP counsel
- Freedom to operate (FTO) opinion letter obtained
- Composition-of-matter patents filed or licensed; coverage confirmed
- Method of use patents and formulation IP documented
- Clear assignment of inventorship from founders, academic collaborators, and prior employers
- License agreements reviewed for milestone obligations, royalty rates, and sublicensing rights
Commercial & Market Due Diligence
- Total Addressable Market analysis sourced from validated databases (EvaluatePharma, GlobalData, etc.)
- Competitive landscape analysis covering both approved drugs and the development pipeline
- Payer landscape and reimbursement strategy outlined for target markets
- Pricing model developed using comparable drug benchmarks
- Key Opinion Leader (KOL) endorsements or scientific advisory relationships in place
- Patient advocacy group engagement documented
Financial Due Diligence
- Cash runway analysis by quarter under base and stress scenarios
- Fully-loaded development budget to the next key value-inflection point
- Grant history: amounts awarded, milestones achieved, compliance maintained
- Cap table is clean and free of major dilution complications
- Financial statements (audited statements strongly preferred for Series A and beyond)
- Sensitivity analysis addressing: what if Phase I is delayed 6 months? What if enrollment is slower than projected?
Part 5: How to Prepare for Series A, B, and C Funding
Equity funding rounds in pharma biotech are structured around specific clinical and regulatory de-risking milestones. Understanding what investors expect at each stage is essential before entering any negotiation.
| Round | Typical Raise | Development Stage | What Investors Need to See |
|---|---|---|---|
| Pre-Seed / Seed | $500K – $5M | Discovery / Lead ID | Proof-of-concept biology, strong founding team, provisional patent, SBIR Phase I as validation signal |
| Series A | $15M – $60M | IND-enabling / Phase I entry | Robust preclinical package, lead compound nominated with ADMET profile, IND filed or underway, regulatory strategy documented, SBIR Phase II strengthens non-dilution story |
| Series B | $40M – $150M | Phase I complete / Phase II initiation | Phase I safety data with MTD established, PK/PD confirming human target engagement, Phase II protocol agreed with FDA, biomarker strategy validated, Big Pharma partnership discussions initiated |
| Series C & Beyond | $100M – $500M+ | Phase II data / Phase III initiation | Positive Phase II proof-of-concept data (the pivotal inflection point), Phase III design finalized with FDA Special Protocol Assessment, commercial-scale manufacturing secured, commercial team being assembled |
The Grant–Equity Interplay
Non-dilutive grant funding is not an alternative to equity — it’s a strategic tool that extends runway, validates science, and reduces dilution at each equity round. A company entering a Series A having completed SBIR Phase I and II has materially de-risked its program on government dollars, enabling a higher valuation and better terms for founders and early investors.
Consider: the average SBIR Phase I + II combined award exceeds $2M, carries 0% equity dilution, and — when combined with Phase I clinical data — can drive a 3–5× valuation uplift on the underlying program. The trade-off is time: grant applications take 3–6 months to prepare and review cycles add further delay. Build your grant calendar into your fundraising timeline from the start.
Part 6: Proposal Preparation Checklist
Use these checklists as a pre-submission quality gate. Each section maps to areas that grant reviewers and investors will scrutinize independently.
Scientific Rigor
- Specific Aims page reviewed by at least two external scientists unfamiliar with your program
- All figures have clear axes, legends, n-values, and statistical tests reported
- Preliminary data is reproducible and generated under GLP conditions where required
- Hypotheses are falsifiable and linked to measurable endpoints
- Alternative interpretations of data are acknowledged and specifically addressed
- References are current (within 5 years for key mechanistic citations)
Innovation & Significance
- Problem statement opens with compelling epidemiological or clinical burden data
- Gap analysis clearly articulates what is specifically missing from current treatments
- Innovation is distinguished from incremental improvement with evidence
- Competitive differentiation documented vs. known pipeline compounds at clinicaltrials.gov
- Patient impact articulated in accessible, non-technical language in the significance section
Approach & Feasibility
- Experimental design follows ARRIVE 2.0 or equivalent guidelines for animal studies
- Power calculations included for all in vivo experiments
- Timeline is realistic — validated by PIs who have run comparable experiments
- Potential pitfalls identified with specific, credible mitigation strategies for each
- Go/No-Go criteria defined for each specific aim
- CRO agreements or vendor quotes in place for all outsourced work
Commercialization (SBIR / BARDA)
- Market size data sourced from published, credible reports with citations
- IP landscape analysis current as of the submission quarter
- Regulatory strategy reviewed by an independent regulatory affairs consultant
- Exit strategy articulated: strategic partnership, licensing, or independent commercialization
- Financial projections include conservative, base, and optimistic scenarios
- Company website, LinkedIn, and public-facing presence are professional and current
Submission Compliance
- Application submitted through Grants.gov / eRA Commons at least 48 hours before the deadline
- All required registrations current: SAM.gov, UEI (formerly DUNS), eRA Commons, NSF Research.gov
- Page limits strictly adhered to — even one page over triggers administrative return without review
- Fonts, margins, and spacing comply with agency-specific formatting requirements
- Conflict of interest disclosures completed for all listed personnel
- IRB / IACUC approvals in place or noted as pending, as applicable
Part 7: Grant Writing Support & Where to Get Help
Even the strongest science needs expert grant writing support. The difference between funded and not-funded often comes down to how clearly ideas are communicated — and how well the application package is assembled.
Free Government Resources
- NIH SEED Office (seed.nih.gov) — Free pre-submission consultations, application review support, and access to TABA resources for all SBIR/STTR applicants
- SBIR.gov Topic Search — Official federal database of all open SBIR/STTR topics across every participating agency, updated each solicitation cycle
- NIH Reporter (reporter.nih.gov) — Searchable database of all funded NIH grants; study successful applications in your disease area and identify Program Officers
- BARDA Industry Days (BID) — Annual conference at which BARDA program managers present current funding priorities. Attending before submitting a BAA response is strongly recommended
Professional Support Services
- Specialist pharma grant writers — Including former NIH study section members and SBIR-experienced writers. Engagement typically begins 6–8 weeks before the submission deadline
- Regulatory affairs consultants — An independent regulatory strategy review by a former FDA reviewer is essential for any SBIR Phase II or BARDA submission that includes clinical development plans
- CRO partnership letters — Letters of support from established CROs (Charles River, Covance, Evotec, etc.) indicating willingness to perform key studies add credibility; budget figures should reference actual CRO quotes
- University technology transfer offices — For academic spinouts, TTOs can assist with IP licensing, provide introduction letters, and in some cases co-apply for grants. Most R1 universities have dedicated life sciences commercialization teams
Quick Reference: Key Submission Deadlines
| Program | Typical Deadlines | Where to Apply |
|---|---|---|
| NIH SBIR / STTR | January 5, April 5, September 5 (annually) | grants.nih.gov / eRA Commons |
| NSF SBIR | Rolling Project Pitches (when open; paused until ~Sep 2026) | seedfund.nsf.gov |
| DoD SBIR / STTR | Monthly openings (first Wednesday of each month) | sbir.gov / defenseinnovationmarketplace.diu.mil |
| BARDA BAA | Rolling / continuous open BAA | sam.gov / barda.hhs.gov |
| EIC Accelerator | 3–4 cut-off deadlines per year | eic.ec.europa.eu |
| CARB-X | Rolling open calls (see website for current timing) | carb-x.org |
| Wellcome Trust | Rolling (scheme-specific; check each program) | wellcome.org/grant-funding |
| Gates Grand Challenges | Topic-specific annual rounds | grandchallenges.org |
State-Level Programs Worth Checking
Before going federal, check your state. Many US states have additional life sciences funding programs: the Massachusetts Life Sciences Center, the California Institute for Regenerative Medicine (CIRM), New York State’s Empire State Development Life Sciences program, and Texas CPRIT for cancer research, among others. State programs often have less competition and faster review cycles than federal mechanisms.
Alex has 20+ years of experience in the CMC space, specializing in CDMO/CRO management, analytical development, technology transfer, quality and regulatory compliance for various drug modalities across multiple product stages.
Reach out to Alex on LinkedIn.
